CAD Consortium Score Calculator

CAD Consortium Score: Comprehensive Explanation and Clinical Context The CAD Consortium Score is a validated clinical tool developed to estimate the pre-test probability of obstructive coronary artery disease (>50% stenosis in at least one major epicardial vessel) in patients with stable chest pain. It replaces older prediction models such as the Diamond–Forrester model, which consistently overestimated risk in the modern era. Model Components The CAD Consortium Clinical Model integrates eight predictors: age, sex, chest pain type, diabetes, hypertension, dyslipidemia, and smoking status.

It generates a patient-specific probability that can be used to decide whether further testing (such as CT coronary angiography) is warranted. Interpretation - <5%: Low risk → No further testing; focus on prevention. - 5–15%: Borderline risk → Consider CTCA if symptoms persist. - 15–50%: Intermediate risk → CTCA recommended. - >50%: High risk → Consider invasive angiography or aggressive management. Clinical Significance Using the CAD Consortium Score allows for a more individualized, evidence-based evaluation of chest pain, minimizing unnecessary invasive testing and improving patient outcomes.

It is endorsed by the European Society of Cardiology (ESC) and the National Institute for Health and Care Excellence (NICE) for the assessment of stable coronary syndromes.